Helix BioPharma Corp HBP Financial and Strategic SWOT Analysis Review [Updated: 19012017] Prices from USD $125

02:52 EST 30 Jan 2017 | BioPortfolio Report Blog

Helix BioPharma Corp HBP Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Helix BioPharma Corp Helix is a biopharmaceutical company with a focus in the field of cancer therapy. The company develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anticancer therapeutic platform has yielded two new drug product candidates, VDOS47 and LDOS47. VDOS47 uses the company's proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and LDOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic nonsmall cell lung cancer NSCLC. It also continues to actively pursue additional novel antibody based technologies for cellbased therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp Key Recent Developments

Dec 13, 2016: Helix BioPharma Announces Fiscal First Quarter 2017 Results
Oct 31, 2016: Helix BioPharma Announces Fiscal 2016 Results
Sep 07, 2016: Helix BioPharma Announces New Director Appointment
Sep 01, 2016: Helix BioPharma Announces CART Poster Presentation at the AACR Conference
Jul 26, 2016: AACR Approves Helix BioPharma's Poster for Presentation at the International Cancer Immunotherapy Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Helix BioPharma Corp HBP Financial and Strategic SWOT Analysis Review [Updated: 19012017] Prices from USD $125


More From BioPortfolio on "Helix BioPharma Corp HBP Financial and Strategic SWOT Analysis Review [Updated: 19012017] Prices from USD $125"

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...